Coherus Biosciences Inc (NASDAQ:CHRS) has been given a consensus recommendation of “Buy” by the eleven analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $31.63.
CHRS has been the topic of a number of recent analyst reports. Zacks Investment Research cut shares of Coherus Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, January 9th. BidaskClub cut shares of Coherus Biosciences from a “buy” rating to a “hold” rating in a report on Thursday, January 25th. ValuEngine upgraded shares of Coherus Biosciences from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 3rd. Citigroup raised their price target on shares of Coherus Biosciences from $23.00 to $25.00 and gave the company a “buy” rating in a report on Friday, March 9th. Finally, Maxim Group restated a “buy” rating and issued a $15.00 price target (down from $20.00) on shares of Coherus Biosciences in a report on Friday, March 9th.
Several institutional investors have recently made changes to their positions in CHRS. Teacher Retirement System of Texas purchased a new position in Coherus Biosciences during the 4th quarter worth approximately $101,000. Landscape Capital Management L.L.C. purchased a new position in Coherus Biosciences during the 4th quarter worth approximately $116,000. Bank of Montreal Can purchased a new position in Coherus Biosciences during the 4th quarter worth approximately $135,000. Ladenburg Thalmann Financial Services Inc. raised its position in Coherus Biosciences by 497.4% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,600 shares of the biotechnology company’s stock worth $168,000 after buying an additional 10,491 shares during the last quarter. Finally, Fox Run Management L.L.C. purchased a new position in Coherus Biosciences during the 4th quarter worth approximately $228,000. 82.70% of the stock is owned by hedge funds and other institutional investors.
Coherus Biosciences (CHRS) traded up $0.35 during trading hours on Friday, hitting $12.50. 595,561 shares of the stock were exchanged, compared to its average volume of 796,836. Coherus Biosciences has a twelve month low of $8.05 and a twelve month high of $24.70. The company has a market cap of $736.73, a PE ratio of -2.75 and a beta of 3.62. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 3.33.
Coherus Biosciences (NASDAQ:CHRS) last released its quarterly earnings results on Thursday, March 8th. The biotechnology company reported ($0.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.02. Coherus Biosciences had a negative net margin of 73.89% and a negative return on equity of 493.03%. equities analysts expect that Coherus Biosciences will post -3 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Coherus Biosciences Inc (CHRS) Receives Consensus Recommendation of “Buy” from Analysts” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/08/coherus-biosciences-inc-chrs-receives-consensus-recommendation-of-buy-from-analysts.html.
About Coherus Biosciences
Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.